Osimertinib with chemotherapy as first-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT)
机构：[1]Department of Respiratory and Critical Care Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China[2]Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[3]Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[4]Department of Pulmonary Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, China台州恩泽医疗中心台州医院[5]Sichuan Cancer Hospital and Institute & Cancer, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, Sichuan, China四川省肿瘤医院[6]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China[7]Thoracic oncology Department, Peking University Cancer Hospital & Institute, Beijing, China
Background: In FLAURA2 study, osimertinib combined with chemotherapy (pemetrexed plus either cisplatin or carboplatin) as first-line(1L) therapy has demonstrated
statistically significant and clinically meaningful progression-free survival (PFS) benefits by approximately 9 months in patients(pts) with EGFR mutation (EGFRm)
advanced NSCLC compared to osimertinib monotherapy. However, the data of diverse
treatment patterns (chemotherapy regimen, number of induction chemotherapy cycles, duration of chemotherapy maintenance, chemotherapy dose intensity, etc.) and
impact on clinical outcome of 1L osimertinib plus chemotherapy in real-world setting
is limited. Further evaluate the effectiveness and safety of osimertinib plus chemotherapy as 1L in real-world setting is very essential for clinical practice.
第一作者机构：[1]Department of Respiratory and Critical Care Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
推荐引用方式(GB/T 7714)：
Han B.,Wang Q.,Zhang B.,et al.Osimertinib with chemotherapy as first-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT)[J].ANNALS OF ONCOLOGY.2024,35:doi:10.1016/j.annonc.2024.10.761.
APA：
Han, B.,Wang, Q.,Zhang, B.,Lv, D.,Yao, W....&Zhuo, M..(2024).Osimertinib with chemotherapy as first-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT).ANNALS OF ONCOLOGY,35,
MLA：
Han, B.,et al."Osimertinib with chemotherapy as first-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT)".ANNALS OF ONCOLOGY 35.(2024)
医学